Tailwinds’ Take: Per Mark Day, “(the Forum) is my first opportunity to publicly express my excitement about biOasis and to discuss our strategies for the Transcend Platform going forward.” Sounds like we are going to start getting more knowledge about the direction of biOasis under the new leadership in the very near future.
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, the chief executive officer of biOasis, will present at the Global Chinese Financial Forum (GCFF) – Shanghai Conference 2017, in Shanghai, China, on June 22, 2017. biOasis Board Chairman, Rob Hutchison, will attend the conference with Dr. Day.
Dr. Day’s presentation, “A Ground-Breaking Platform for the Delivery of Therapeutic Compounds Across the Blood-Brain Barrier,” will be attended by a wide assortment of private investors, life science companies and investment funds. The GCFF – Shanghai Conference 2017 will be held concurrently with China’s largest pharma-focused event, the CPhI China Conference.
“The Chinese pharmaceutical industry is one of the largest in the world with double-digit growth and exceptional opportunities for biOasis,” said Dr. Mark Day, CEO, biOasis. “The GCFF – Shanghai Conference 2017 offers biOasis the opportunity to introduce our Transcend Platform to executives and scientists from many of China’s largest life science companies and to begin building alliances throughout Asia.”
“On a personal note, the conference is my first opportunity to publicly express my excitement about biOasis and to discuss our strategies for the Transcend Platform going forward,” said Dr. Day. “I have described Transcend as one of the most unique and promising blood-brain barrier technologies of our time. I look forward to meeting my industry colleagues and establishing new ones, placing biOasis in the mix of growth opportunities the Chinese pharmaceutical industry can offer us.”
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.
Read more at http://www.stockhouse.com/companies/bullboard?symbol=v.bti&postid=26343949#ljyeZdIIRjhPzOH3.99